Natixis Intra Cellular Therapies, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Natixis holds 727 shares of ITCI stock, worth $59,454. This represents 0.0% of its overall portfolio holdings.
Number of Shares
727
Previous 1,162
37.44%
Holding current value
$59,454
Previous $79,000
32.91%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ITCI
# of Institutions
378Shares Held
84.1MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$787 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$517 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$432 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$315 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$249 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $7.72B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...